The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 30,439 |
| Depreciation and amortization | 85,218 |
| Loss on extinguishment of debt | 0 |
| Amortization of debt issuance costs and discounts | 1,768 |
| Non-cash operating lease expense | 4,007 |
| Stock-based compensation expense | 76,626 |
| Deferred income taxes | 20,071 |
| Loss on operating lease assets | 4,409 |
| Loss on disposal of capitalized software | 0 |
| Loss on minority equity interest investment | 0 |
| Other | 1,810 |
| Accounts receivable | 88,016 |
| Prescription reimbursement assets | 75,387 |
| Prepaid expenses and other assets | 8,387 |
| Accounts payable | 4,103 |
| Prescription reimbursement liabilities | 114,341 |
| Accrued expenses and other current liabilities | 1,185 |
| Operating lease liabilities | -6,269 |
| Other liabilities | 1,986 |
| Net cash provided by operating activities | 167,904 |
| Purchase of property and equipment | 3,521 |
| Acquisitions | 43,440 |
| Capitalized software | 70,499 |
| Other | 2,500 |
| Net cash used in investing activities | -119,960 |
| Proceeds from long-term debt | 0 |
| Payments on long-term debt | 5,000 |
| Payments of debt issuance costs | 0 |
| Repurchases of class a common stock | 216,372 |
| Proceeds from exercise of stock options | 61 |
| Employee taxes paid related to net share settlement of equity awards | 14,467 |
| Proceeds from employee stock purchase plan | 1,308 |
| Net cash used in financing activities | -234,470 |
| Net change in cash and cash equivalents | -186,526 |
| Beginning of period | 448,346 |
| End of period | 261,820 |
GoodRx Holdings, Inc. (GDRX)
GoodRx Holdings, Inc. (GDRX)